

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 6, 2009
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 6, 2009.

2. Welcome

Debbie Tapley, R.Ph. called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Ed Behling, M.D.
Greg Browning, M.D.
Jody Bollinger, M.D.
Joe Horvath, M.D.

Kelly Jones, Pharm.D.
Jim Lindsay, M.D.
Sara Lindsey, M.D.
Thomas Phillips, R.Ph.

Tan Platt, M.D.
Charles Raine, M.D.
Debbie Tapley, R.Ph.

DHHS Staff Present:

Emma Forkner, Medicaid Director
Marion Burton, M.D.
James M Assey, R.Ph.
Mike Blakely, R.Ph.
Deidra Singleton, J.D.
Nikole Boland, J.D.

Other Representation:

First Health Services – Mary Roberts, R.Ph.
First Health Services – Bryan Amick, PharmD
Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, November 5, 2009.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

Company	Speaker	Drug
Allergan	Greg Kitchens, PharmD	Acular®, Acular LS®
Par Pharmaceuticals	Naomi Musaji, BS, PharmD	Megace ES®
Self	Annette Williams Lynn, MD	Tazorac

C. Drug Classes for Review

Mary Roberts, R.Ph., First Health Services Corporation, led the discussion for the following drug classes:

- Topical NSAIDs and Anesthetics
- Ophthalmic NSAIDs
- Calcitonins
- Progestins Used for Cachexia
- Ophthalmic Mast Cell Stabilizers
- Topical Antivirals
- Protein Tyrosine Kinase Inhibitors
- Ranexa
- Intranasal Antihistamines
- Soriatane
- Topical Retinoids and Combinations

The chart below represents the recommendations from the P & T Committee:

<i>Topical NSAID's and Anesthetics</i>	
Preferred	Non-Preferred
	Flector® Patch Lidoderm® Patch Voltaren® Gel
<i>Ophthalmic NSAID's</i>	
Preferred	Non-Preferred
Acular® Acular LS® Acular PL® Diclofenac Sodium Flurbiprofen Sodium Nevanac®	Ocufen® Voltaren® Drops Xibrom®

<i>Calcitonins</i>	
Preferred	Non-Preferred
Fortical® Nasal Spray Calcitonin Salmon Nasal Spray	Miacalcin® Nasal Spray
<i>Progestins for Cachexia</i>	
Preferred	Non-Preferred
Megestrol Oral Suspension	Megace® Oral Suspension Megace ES® Oral Suspension
<i>Ophthalmic Mast Cell Stabilizers</i>	
Preferred	Non-Preferred
Alamast® Alocril® Alomide® Cromolyn Sodium	Crolom® Opticrom®
<i>Topical Antivirals</i>	
Preferred	Non-Preferred
Abreva® Zovirax® Ointment	Denavir® Zovirax® Cream
<i>Protein Tyrosine Kinase Inhibitors</i>	
Preferred	Non-Preferred
Gleevec®	Spryel® Sutent® Tasigna®
<i>Ranexa</i>	
Preferred	Non-Preferred
Ranexa®	
<i>Intranasal Antihistamines</i>	
Preferred	Non-Preferred
Astelin® Astepro®	Patanase®
<i>Soriatane</i>	
Preferred	Non-Preferred
Soriatane CK®	
<i>Committee would like to table this class and discuss again in August after information can be obtained regarding utilization in women of child-bearing years. FHSC to report back.</i>	

Class for Re-Review

<i>Topical Retinoids and Combinations</i>	
Preferred	Non-Preferred
Differin® Epiduo® Retin-A Micro® Retin-A Mircro® Pump Tretinoin	Altinac® Atralin® Avita® Retin A® Tazorac® Tretin X® Ziana®

5. Old Business

Mary Roberts presented requested information from the last meeting. Patients with age or gender that appeared inappropriate for some medications reviewed at last meeting. Provider Representatives have been calling pharmacies to determine diagnosis. A few were billed to incorrect Medicaid ID – those have been corrected. Others were the correct ID, but pharmacists did not have diagnosis. DHHS is considering adding age and gender edits to some of these medications and to others.

6. New Business

Ms. Forkner addressed the committee regarding the Medicaid budget concerns and her goals for the upcoming year. Many topics were discussed including the new enhanced federal match, carve out of pharmacy benefit from the MCO environment, cigarette tax and the federal stimulus package.

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

- Topical NSAIDs and Anesthetics
 - Ophthalmic NSAIDs
 - Calcitonins
 - Progestins Used for Cachexia
 - Ophthalmic Mast Cell Stabilizers
 - Topical Antivirals
 - Protein Tyrosine Kinase Inhibitors
 - Ranexa
 - Intranasal Antihistamines
 - Topical Retinoids and Combinations

8. Closing Comments

The next meeting will be held on Wednesday, August 5, 2009 at 4:00 p.m. at the same location.

9. Adjournment

The meeting adjourned at 6:05p.m.